Landscape of Mitochondria Genome and Clinical Outcomes in Stage 1 Lung Adenocarcinoma

doi:10.3390/cancers12030755

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24917

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24917

Title:	Landscape of Mitochondria Genome and Clinical Outcomes in Stage 1 Lung Adenocarcinoma
Authors:	Raghav, L;Chang, YH;Hsu, YC;Li, YC;Chen, CY;Yang, TY;Chen, KC;Hsu, KH;Tseng, JS;Chuang, CY;Lee, MH;Wang, CL;Chen, HW;Yu, SL;Su, SF;Yuan, SS;Chen, JJW;Ho, SY;Li, KC;Yang, PC;Chang, GC;Chen, HY
Keywords:	mitochondria;lung adenocarcinoma;EGFR-activating mutations;somatic mutations;prognosis
Date:	2020
Issue Date:	2022-08-09T08:10:07Z (UTC)
Publisher:	MDPI
Abstract:	Risk factors including genetic effects are still being investigated in lung adenocarcinoma (LUAD). Mitochondria play an important role in controlling imperative cellular parameters, and anomalies in mitochondrial function might be crucial for cancer development. The mitochondrial genomic aberrations found in lung adenocarcinoma and their associations with cancer development and progression are not yet clearly characterized. Here, we identified a spectrum of mitochondrial genome mutations in early-stage lung adenocarcinoma and explored their association with prognosis and clinical outcomes. Next-generation sequencing was used to reveal the mitochondrial genomes of tumor and conditionally normal adjacent tissues from 61 Stage 1 LUADs. Mitochondrial somatic mutations and clinical outcomes including relapse-free survival (RFS) were analyzed. Patients with somatic mutations in the D-loop region had longer RFS (adjusted hazard ratio, adjHR = 0.18, p = 0.027), whereas somatic mutations in mitochondrial Complex IV and Complex V genes were associated with shorter RFS (adjHR = 3.69, p = 0.012, and adjHR = 6.63, p = 0.002, respectively). The risk scores derived from mitochondrial somatic mutations were predictive of RFS (adjHR = 9.10, 95%CI: 2.93-28.32, p < 0.001). Our findings demonstrated the vulnerability of the mitochondrial genome to mutations and the potential prediction ability of somatic mutations. This research may contribute to improving molecular guidance for patient treatment in precision medicine.
URI:	http://dx.doi.org/10.3390/cancers12030755 https://www.webofscience.com/wos/woscc/full-record/WOS:000530232300231 https://ir.csmu.edu.tw:8080/handle/310902500/24917
Relation:	CANCERS ,2020 ,v12 ,issue 3
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	198	View/Open

Loading...